LIN BIOSCIENCE, INC.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. LBS-008
2. LBS-007
3. LBS-002
4. LBS-009
2. LBS-007
3. LBS-002
4. LBS-009
Founded Year
2016
Unified Business No.
43814765
Status
Active
Number of Employees
0
Total Paid-in
Capital
829,200,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2018)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Lin BioScience, Inc. (TPEx: 6696) is a drug development company established in 2016 focusing on advancing novel therapies and first-in-class treatments for unmet medical needs in various therapeutic areas such as ophthalmology, oncology, and metabolic diseases. Lin BioScience’s pipeline currently consists of four candidate drugs. LBS-008 treating dry age-related macular degeneration and Stargardt disease, and LBS-009 treating nonalcoholic steatohepatitis are developed by its subsidiary Belite Bio Inc. (Nasdaq: BLTE). LBS-007 treating acute leukemias and solid tumors, and LBS-002 treating glioblastoma and the metastasis are developed by Lin BioScience, inc..
